DOXORUBICINA ACCORD HEALTHCARE ITALIA 2 mg/ml concentrato per soluzione per infusione

DRUG2 trials

Sponsors

Azienda Ospedaliero Universitaria Pisana, Istituto Di Ricerche Farmacologiche Mario Negri

Conditions

HER2-negativePleural carcinosisbreast carcinomaestrogen receptor–positiveneoadjuvant chemotherapystage II–IIIB

Phase 2

Pressurized intrathoracic aerosol chemotherapy (PITAC) in patients with malignant pleural effusion: a single-center phase II trial. PITAC_ MaPEPi

WithdrawnCTIS2024-511255-17-00

Azienda Ospedaliero Universitaria PisanaPleural carcinosis

Target: 40Updated: 2025-12-22

A Pragmatic Phase II Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2− Early Breast Cancer Using Oncotype DX and Abemaciclib - VIOLET trial

Not yet recruitingCTIS2026-525457-37-00

Istituto Di Ricerche Farmacologiche Mario NegriHER2-negative, stage II–IIIB, neoadjuvant chemotherapy +2

Target: 150Updated: 2026-10-16